Gene Therapy Data for BCG-Unresponsive NMIBC

Author(s):

Key Takeaways

BCG-unresponsive NMIBC is defined by persistent or recurrent high-grade tumors or carcinoma in situ after adequate BCG therapy.
This condition requires alternative therapeutic strategies or radical cystectomy due to the failure of BCG treatment.
BCG-responsive NMIBC achieves and maintains a complete response following BCG therapy, contrasting with the unresponsive form.

Katie S. Murray, DO, discusses the promising clinical trial data showing that over 50% of patients with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) experience a complete response after 3 months of treatment, comparing these outcomes with her own clinical experience, and highlights the importance of long-term follow-up to assess the durability of response in patients receiving newer therapies.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Overview of BCG-Unresponsive NMIBC

EP: 2.Challenges of BCG-Unresponsive NMIBC

EP: 3.Standard Treatment Options for BCG-Unresponsive NMIBC

EP: 4.Unresponsive NMIBC: Gene Therapies

EP: 5.Gene Therapy Considerations for BCG-Unresponsive NMIBC

Now Viewing

EP: 6.Gene Therapy Data for BCG-Unresponsive NMIBC

EP: 7.BCG-Unresponsive NMIBC: Insights for Newer Treatment Modalities

EP: 8.Addressing Challenges in BCG-Unresponsive NMIBC: Overview and Unmet Needs

EP: 9.Current Treatment Options for BCG-Unresponsive NMIBC

EP: 10.The Impact of Targeted Gene Therapy and Nadofaragene Firadenovec on BCG-Unresponsive NMIBC

EP: 11.Advancements in BCG-Unresponsive NMIBC and the Impact of Trial Results and Long-Term Follow-Up

EP: 12.Discussing Treatment Options for BCG-Unresponsive NMIBC

EP: 13.Cost-Effectiveness and Patient Support in Treating BCG-Unresponsive NMIBC

EP: 14.Reducing Resource Expenditure in Clinics with New Gene Therapies for BCG-Unresponsive NMIBC

EP: 15.Enhancing Access to BCG-Unresponsive NMIBC Treatments

EP: 16.Navigating BCG-Unresponsive NMIBC and Emerging Therapies

EP: 17.The Impact of Gene Therapy and Advancements in BCG-Unresponsive NMIBC Treatment

EP: 18.BCG-Unresponsive NMIBC: Balancing Care and Financial Considerations

EP: 19.Navigating Treatment Choices and Financial Considerations in BCG-Unresponsive NMIBC

EP: 20.Adoption of New Treatments for BCG-Unresponsive NMIBC

EP: 21.Future Directions of BCG-Unresponsive NMIBC Management

Data for newer therapies have shown that more than 50% of patients with BCG-unresponsive NMIBC experience a complete response after just 3 months of treatment. What are your thoughts on these findings?
1. How do these clinical trial outcomes compare with what you see in your clinical practice when treating patients with newer therapies
Discuss the importance of long-term follow-up for patients receiving these newer treatments.
a. What is your experience in terms of durability of response?